Urinary cysteinyl leukotriene e 4 is associated with increased risk for pain and acute chest syndrome in adults with sickle cell disease

20Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Leukotriene E 4 (LTE 4) levels are associated with rate of pain episodes in children with sickle cell disease (SCD). Because complications of SCD manifest differently in adults than children, we examined a cohort of adults with SCD to determine the relationship between baseline LTE 4 and SCD-related morbidity. Baseline LTE 4 levels were associated with increased rates of pain and acute chest syndrome (ACS) episodes, when those with LTE 4 values in the highest tertile were compared with those in the lowest tertile (pain: risk ratio 7.1, 95% CI 1.8-27.5, P = 0.005; ACS: risk ratio 12.2, 95% CI 2.1-69.8, P = 0.005). © 2008 Wiley-Liss, Inc.

Cite

CITATION STYLE

APA

Field, J. J., Krings, J., White, N. L., Yan, Y., Blinder, M. A., Strunk, R. C., & Debaun, M. R. (2009). Urinary cysteinyl leukotriene e 4 is associated with increased risk for pain and acute chest syndrome in adults with sickle cell disease. American Journal of Hematology, 84(3), 158–160. https://doi.org/10.1002/ajh.21348

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free